BadCuda
2 days ago
$200 million during the period. Upon the completion of the plant startup requirements, Sharps is planning for product deliveries to begin late in the second quarter of 2025 with revenue expected to total more than $35 million for the first twelve months of sales.
After dilution on Wednesday
50 million outstanding
12 million float
35 million sales (2025 /12 mil float = 2.91$/share value ? Maybe I'm crazy , that must be off -maybe That's why we've seen 10-20 million share trading days (short selling bastards). What's stopping this from
Popping , guess aegis could short its own stock they now will be 80%owners . Next quarterly report is March 31 , could be a wild ride gotta fill that gap down from 1.40 area sometime . Williams% bottoming way over sold -95 , Macd slowly rolling over , 20 dma is 1.09 just needs volume . Aegis's ball - we'll see
georgie18
2 weeks ago
STSS...42s hitting here...🥳
georgie18
Member Level
Re: georgie18 post# 389415
Thursday, January 30, 2025 3:40:05 PM
Post#
389419
of 389421
STSS...4054...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 31215
Thursday, January 30, 2025 2:32:34 PM
Post#
31222
of 31233
STSS...3884...Red to Green Here...🥳
georgie18
Member Level
Re: georgie18 post# 389302
Thursday, January 30, 2025 1:53:35 PM
Post#
389410
of 389414
STSS...3714...Trying Red to Green here off that .33 range dip...🥳
subslover
2 months ago
Sells out inventory. Hmmmmmmmm: Sharps Technology Signs Sales Agreements to Support Major European Healthcare Network and Sells Out Its Inventory for SecureGard
Signed multiple agreements to sell its SecureGard syringe inventory, with initial shipments and revenue commencing in early December
Agreements also include new forecasted orders and commitments for all current SecureGard capacity, to begin in Q2 2025
The SecureGard agreements will strengthen the potential revenue curve for the Hungary Operation starting in 2024
NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, has begun deliveries of its 1mL and 3mL SecureGard safety syringes under the new sales agreements with a prominent European medical supply company serving Poland, Slovakia, and the Czech Republic. To meet demand in the region, Sharps’ customer has requested additional deliveries by year-end 2024 and committed to purchasing all available plant inventory by Q1 2025.
As a supplier to the largest network of hospitals and outpatient clinics in Central and Eastern Europe, the customer plans to purchase Sharps’ entire existing inventory of 1mL and 3mL SecureGard inventory warehoused in Hungary. This would be followed by new production orders starting in Q2 2025. These orders will consume all currently available SecureGard production capacity of 35 million units at the Hungary manufacturing facility. The customer has also expressed interest in Sharps’ U.S. inventory to fulfill a need for safety syringe supplies in Northern Africa.
The demand for Sharps’ innovative injection solutions continues to grow rapidly, with injectables remaining the preferred delivery method for therapies such as vaccines, biologics, weight loss and maintenance, ophthalmic and cosmetic applications, gene therapies, and diabetes and inflammatory disease management. With increasing levels of interest and potential demand for the Company’s high-quality smart safety syringe products in the region, Sharps is collaborating with both government and private investment sources in Hungary to expand the current manufacturing footprint and take advantage of the need to increase both SecureGard and SoloGard manufacturing capacity. The expansion will be planned to increase the annual SecureGard capacity to more than 100 million units, and the SoloGard capacity to more than 125 million units.
Sharps’ SecureGard and SoloGard product lines focus on low waste and ultra-low waste syringe technologies that also incorporate active safety features to fill the healthcare industry’s demand for the highest quality drug delivery solutions.